US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome
The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, ...
MPR23h
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
BioPharma Dive5d
First Prader-Willi drug to reduce hunger approved by FDA
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
MedPage Today on MSN4d
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...
Healio4d
FDA approves first therapy to treat hyperphagia in Prader-Willi syndrome
The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with ...
Disability Scoop4d
FDA Green-Lights First Treatment For Prader-Willi Syndrome
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
STAT4d
NIH director targets misinformation research as more turmoil rocks health agencies
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Tiny Silicon Valley drugmaker soars on FDA win to treat never-ending hunger
Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...
STAT5d
Soleno Therapeutics’ ‘life-changing’ rare-disease drug approved
The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndromeManagement to host conference call and webcast today, ...
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ...